Secnidazole is a nitroimidazole anti-infective used to treat bacterial vaginosis and trichomoniasis. It is taken orally. Structurally it actually methyl-metronidazole. Effectiveness in the treatment of dientamoebiasis has been reported. It has also been t shown to act via bioreduction of the nitro group in anaerobic organisms to generate reactive intermediates that damage microbial DNA and inhibit nucleic acid synthesis. Pharmacokinetically secnidazole is well absorbed after oral administration and exhibits a relatively long elimination half-life compared with some other nitroimidazoles which supports single-dose or short-course regimens; it is metabolized hepatically and eliminated in urine and feces. Typical clinical dosing is a single 2 g oral dose for uncomplicated trichomoniasis and bacterial vaginosis in adults, with adverse effects most commonly limited to gastrointestinal discomfort, metallic taste and headache; use should follow local prescribing guidance and consider contraindications and potential drug interactions.
Parent: Secnidazole
Technical control of secnidazole requires monitoring of related compounds and degradation products including N-oxide species, dealkylated and dehydro metabolites, ring-opened degradation products and trace levels of structurally related nitroimidazole analogs such as metronidazole where cross-contamination is possible. Typical analytical acceptance criteria used in API quality control are: each individually identified related compound not more than 0.5% w/w, any unspecified single impurity not more than 0.10% w/w, total impurities not more than 2.0% w/w. Residual solvents and elemental impurities should comply with ICH Q3C and Q3D limits respectively. Specifications and limits may vary between manufacturers and pharmacopeial monographs so release testing should reference the applicable regulatory monograph and stability data.
Secnidazole tablets are used orally to treat infections caused by anaerobic protozoa and bacteria, most commonly bacterial vaginosis and trichomoniasis, and have reported activity against dientamoebiasis.
No, Both are nitroimidazoles with similar mechanisms but they are distinct chemical entities with different pharmacokinetic profiles and dosing; secnidazole has a longer half-life and is often given as a single dose, while metronidazole typically requires multiple doses daily.
Many approved regimens use a single 2 g oral dose for uncomplicated adult trichomoniasis or bacterial vaginosis; alternative regimens may be used in special populations or for different indications so follow the product labeling or prescriber instructions.
Secnidazole has reported effectiveness for certain protozoan infections such as dientamoebiasis and can be active against some amoebic or flagellate parasites, but treatment choice should be guided by the identified organism, susceptibility data and clinical guidelines.
